Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Joseph Tucker, Chief Executive Officer and Director of Enveric ...

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 ...

Hong Kong health authorities have apologised for mistakenly giving pneumococcal vaccines to two children at a health centre ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.

The Department of Health is investigating and following up on an incident in which the pneumococcal vaccine was mistakenly ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies ...

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s highlights in H ...

Research analysts at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report released on Wednesday. The brokerage set a “hold” rating on the ...